Erytech Pharma announces positive safety review for ERY-ASP
Tuesday, July 21, 2015
Erytech Pharma SA announces positive safety review for ERY-ASP in its phase 2 study in pancreatic cancer.
* DSMB recommends continuation of enrollment in phase II pancreatic cancer study after safety review of first 24 patients treated.
* Says results of this phase II clinical trial could pave way for treatment of other solid tumors.
reuters.com
